IL312037A - Endoxifen for treatment of cancers - Google Patents

Endoxifen for treatment of cancers

Info

Publication number
IL312037A
IL312037A IL312037A IL31203724A IL312037A IL 312037 A IL312037 A IL 312037A IL 312037 A IL312037 A IL 312037A IL 31203724 A IL31203724 A IL 31203724A IL 312037 A IL312037 A IL 312037A
Authority
IL
Israel
Prior art keywords
endoxifen
cancer
treatment
concurrent
treating
Prior art date
Application number
IL312037A
Other languages
English (en)
Hebrew (he)
Original Assignee
Atossa Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atossa Therapeutics Inc filed Critical Atossa Therapeutics Inc
Publication of IL312037A publication Critical patent/IL312037A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL312037A 2021-10-28 2022-10-27 Endoxifen for treatment of cancers IL312037A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163272869P 2021-10-28 2021-10-28
PCT/US2022/048061 WO2023076496A1 (en) 2021-10-28 2022-10-27 Endoxifen for treatment of cancers

Publications (1)

Publication Number Publication Date
IL312037A true IL312037A (en) 2024-06-01

Family

ID=86158538

Family Applications (1)

Application Number Title Priority Date Filing Date
IL312037A IL312037A (en) 2021-10-28 2022-10-27 Endoxifen for treatment of cancers

Country Status (10)

Country Link
US (1) US20250041245A1 (enExample)
EP (1) EP4422608A4 (enExample)
JP (1) JP2024541900A (enExample)
KR (1) KR20240093500A (enExample)
CN (1) CN118159259A (enExample)
AU (1) AU2022378576A1 (enExample)
CA (1) CA3232972A1 (enExample)
IL (1) IL312037A (enExample)
MX (1) MX2024005220A (enExample)
WO (1) WO2023076496A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022232924A1 (en) * 2021-03-11 2023-07-06 Atossa Therapeutics, Inc. Endoxifen for treatment of ovarian cancer
CN117338780A (zh) * 2023-09-21 2024-01-05 中国人民解放军海军军医大学 帕罗西汀在制备抗肿瘤药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013033430A1 (en) * 2011-09-02 2013-03-07 Wake Forest School Of Medicine Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof
EP2773340B1 (en) * 2011-11-04 2020-01-08 Myron R. Szewczuk Use of neu1 sialidase inhibitors in the treatment of cancer
DE102015222031A1 (de) * 2015-11-10 2017-05-11 Robert Bosch Gesellschaft Für Medizinische Forschung Mbh Synthese von (Z)-Endoxifenhydrochlorid
WO2017127442A1 (en) * 2016-01-18 2017-07-27 The Regents Of The University Of California Methods for treating cancer with rorgamma inhibitors
JP7662204B2 (ja) * 2019-07-03 2025-04-15 アトッサ・セラピューティクス・インコーポレイテッド エンドキシフェンの徐放性組成物
CN115087466A (zh) * 2019-12-12 2022-09-20 森迪生物科学公司 用于细胞的调控装甲的方法和组合物
AU2022232924A1 (en) * 2021-03-11 2023-07-06 Atossa Therapeutics, Inc. Endoxifen for treatment of ovarian cancer
CN119300811A (zh) * 2022-04-26 2025-01-10 阿托萨治疗学公司 高剂量因多昔芬制剂和使用方法

Also Published As

Publication number Publication date
WO2023076496A1 (en) 2023-05-04
EP4422608A4 (en) 2025-09-24
US20250041245A1 (en) 2025-02-06
EP4422608A1 (en) 2024-09-04
CA3232972A1 (en) 2023-05-04
JP2024541900A (ja) 2024-11-13
MX2024005220A (es) 2024-05-16
KR20240093500A (ko) 2024-06-24
CN118159259A (zh) 2024-06-07
AU2022378576A1 (en) 2024-03-28

Similar Documents

Publication Publication Date Title
WO2020102804A3 (en) Pharmaceutical combination for treatment of cancer
WO2018102687A3 (en) Combination therapy for treating cancer
BR112022002609A2 (pt) Métodos de tratamento de tumores estromais gastrointestinais
EA202092343A1 (ru) Лечение гнойного гидраденита с использованием ингибиторов jak
JP2018127467A5 (enExample)
IL300151A (en) Combinations for cancer treatment
WO2009067397A3 (en) Treatment for solid tumors
NO20053782L (no) Behandling av kreft med 2-deoksyglukose
WO2021207723A3 (en) Methods of treating diabetic kidney disease
MX2025003477A (es) Uso de reboxetina para el tratamiento de narcolepsia
BR112018070017A2 (pt) métodos de tratamento de cânceres pediátricos
IL319182A (en) Deuterium-enriched pirfenidone and methods of using it
EP4427738A3 (en) Dosing protocols and regimens for aminosterol treatment
SE0300971D0 (sv) Nitric oxide in treatment of inflammation
WO2019118779A3 (en) Peptides and other agents for treating pain and increasing pain sensitivity
WO2021011844A3 (en) Combination cancer therapy agents and methods
WO2023196584A3 (en) Endocytosis inhibitors and their use for pain treatment
WO2020101790A3 (en) Methods of using a phenoxypropylamine compound to treat pain
MX2023003258A (es) Tratamiento de enfermedades mediadas por nf-kb.
EA202192928A1 (ru) Терапевтическое лекарственное средство для лечения дискинезии
EA202193211A1 (ru) Лечение синуклеопатий
WO2023019095A3 (en) Momelotinib combination therapy
IL307842A (en) Methods and compositions for treating glioblastoma
UY39593A (es) Tratamiento para tumores sólidos malignos
FI4003533T3 (fi) Multifokaalisen syövän hoitomenetelmiä